Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells and Antibodies in Drug Discovery Europe 2018

Peter O'Brien's Biography



Peter O'Brien, Head of Clinical Pathology, University College Dublin

Peter O’Brien, DVM, PhD, DVSc, Diplomate ECVCP was born in Toronto Canada of Irish and English parents. He got veterinary training in Canada, PhD at Minnesota, and certification in vetclinpath at Ontario’s Vet College where he became Associate Professor. After 7 years here, he moved into tox and headed toxclinpath at P&G-Cincinnatti, then SmithKline-Beecham-Welwyn, then Pfizer-Sandwich. After 11 years in tox, he returned to academia where he serves as clinical pathologist at Dublin Vet School. Peter is past president of European Society (ESVCP) / College (ECVCP) for Veterinary Clinical Pathology and the European Board for Veterinary Specialization (EBVS) and is the current Scientific Secretary for the Association for Comparative Clinical Pathology (ACCP). In 2008, he established Advanced Diagnostics Laboratory, Inc. (ADL), for specialised (tox)clinpath testing. His >150 research papers focus on predicting human toxicity with cytotoxicity, and on cardiac, muscle, liver and pancreatic biomarkers. His role has been with conference management, education and examination for all the above organisations. He is recipient of annual awards for outstanding contributions to clinical pathology from DACC (American Association for Clinical Chemistry, Division of Animal Clinical Chemistry) and the ESVCP. He is third-dan black-belt in shotokan karate and has run a karate club with his three black-belt children for 10 years.

Peter O'Brien Image

High-Content Screening for Adverse Cytologic Effects

Friday, 25 May 2018 at 09:30

Add to Calendar ▼2018-05-25 09:30:002018-05-25 10:30:00Europe/LondonHigh-Content Screening for Adverse Cytologic EffectsStem Cells and Antibodies in Drug Discovery Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

The first, highly-effective, high-content-screening (HCS) for adverse cytologic effect was reported a decase ago (Arch Toxicol 2006, 80, 580). Success was attributed to simultaneous measurement of multiple “cytobiomarkers”, use of human cells that can metabolise drugs, 72 h exposure for slow toxicants, exposure to wide-ranging concentrations,  and normalizing toxic  to efficacious concentration. Many HCS studies now support this approach as necessary in predictive toxicology, as does review of literature since the ?rst cytotoxicity assay was reported 100 years ago.  A subset of the original toxicants was reanalyzed using the original HCS confirming high sensitivity and speci?city across locations, technologies, sta?, laboratories, and time. A protocol is demonstrated for operational validation of the HCS within labs to document pro?ciency and quality management.


Add to Calendar ▼2018-05-24 00:00:002018-05-25 00:00:00Europe/LondonStem Cells and Antibodies in Drug Discovery Europe 2018Stem Cells and Antibodies in Drug Discovery Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com